Treatment patterns and clinical outcomes among patients with relapsed/refractory classical Hodgkin’s lymphoma Supplementary Material Regimen Distribution Supplement

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA sponsored this study and provided financial support for the conduct of the research and for preparation of the article. AR Nisbett and S Gautam are employees of ConcertAI and report research funding from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA to their institution. X Yang, P Squires, K Desai, M Raut, and A Nahar are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and hold stock or stock options in Merck & Co., Inc., Kenilworth, NJ, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.